Cellular Origins has initiated a partnership with supplier of automated fill-finish equipment, 3P innovation.
The cell and gene therapy manufacturing company will now integrate 3P’s cryovial filling platform, cryoFIL into its Constellation robotic system.
This will allow the robot to fill cryovials automatically in a sterile environment.
3P’s cryoFIL platform can streamline the cell and gene therapy (CGT) manufacturing process, while offering closed loop filling and 100% weight verification of all product yields.
The technological integration will facilitate the automation of filling processes involving vials and other open format containers, which aims to enhance the efficiency of their production.
The integration of cryoFIL will reduce the requirement for manual — and sometimes challenging — process steps in the cell and gene therapy manufacturing procedure.
This will reduce the time and labour investment of CGT production, while also potentially lowering costs.
Cellular Origins’ CEO, Dr Edwin Stone, commented: “Our collaboration with 3P Innovation will allow us to address the most difficult challenges in the field. 3P shares our belief that embracing automation is the key to addressing the manufacturing bottleneck and improving accessibility to life-changing cell and gene therapies. By collaborating, we can work towards the industrialisation of CGT manufacturing.”
Dr Dave Seaward, Founder, 3P innovation, commented: “Several years ago, we recognised that automation would be a key factor in reducing costs and expanding access to cell and gene therapies. This insight drove us to innovate and transform our large aseptic fill-finish equipment into benchtop formats tailored for this emerging sector. We are delighted to be working alongside Cellular Origins, combining the benefits of cryoFIL and Constellation to propel our industry forward and revolutionise advanced therapy manufacturing.”
[Image credit: Cellular Origins]
